Pediatric Cancer News Creative arts therapy can ease procedural anxiety in pediatric patients undergoing their first year of cancer treatment, a study suggests.
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
New research has revealed disparities in access to cancer care among children, adolescents, and young adults in the United States.
Pediatric oncologists often choose not to provide prognostic information when discussing a new cancer diagnosis, a new study suggests.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Recurrence-free survival and overall survival rates were similar in children and adolescents with melanoma.
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR T-cell therapy outcomes in patients with B-ALL.
Crizotinib plus chemotherapy appears effective for pediatric patients with newly diagnosed ALCL, but the combination increases the risk of thrombosis.
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
Research suggests hippocampal-sparing radiation may be feasible for pediatric patients with medulloblastoma because the risk of peri‐hippocampal recurrence is low.
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
Omburtamab is an investigational radiolabeled monoclonal antibody designed to target tumor cells that express B7-H3.
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
The new dosing option was approved based on data from a phase 2/3 trial.
Children and adolescents with medulloblastoma frequently suffer from neuroophthalmological sequelae, a single-center study suggests.
Patterns of relapse are similar in patients with standard-risk and high-risk medulloblastoma, a review suggests.
Tovorafenib produced responses in young patients with progressive or recurrent BRAF-altered low-grade glioma in a phase 2 trial.
The approval was based on data from the open-label phase 3 AHOD1331 trial.
The SAFER program is helping Ukrainian children with cancers and other blood disorders to continue their therapy in Ukraine or at centers in Europe and North America.
Survivors of Wilms tumor are more likely than the general population to experience chronic health conditions, a study suggests.
Load More